Burn, Coagulation, Blood
Conditions
Keywords
burn, coagulation, Thromboelastography
Brief summary
This pilot study examines the use of thromboelastography (TEG), a specialized blood test, to evaluate clotting abnormalities in burn patients. The study aims to understand how burn injuries impact the body's ability to form and break down blood clots over time. Specifically, the investigators will research whether the percentage of total body surface area burned (%TBSA) is associated with changes in blood clotting, track the evolution of clotting patterns during the first four weeks following a burn injury, and explore whether these changes can predict recovery or complications. By providing new insights into clotting dynamics in burn patients, the study seeks to improve diagnostic methods, enhance monitoring strategies, and guide treatments to optimize patient care and outcomes.
Interventions
DIAGNOSTIC_TESTThromboelastography
All participants will receive this intervention. Thromboelastography (TEG) is a blood test that provides a detailed assessment of the clotting process, measuring how blood clots form, strengthen, and dissolve. It offers real-time insights into a patient's coagulation status, helping to identify clotting disorders and guide treatment decisions.
Sponsors
Francesco Egro
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients admitted with acute burn injuries * Aged 18 years and older * Provided consent to participate in the study
Exclusion criteria
* Patients with a history of venous thromboembolism or hyper/hypocoagulopathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Thromboelastography | Duration of hospital length of stay, up to 28 days | Thromboelastography (TEG) evaluates blood's clotting ability by measuring the strength and elasticity of a clot over time, producing a dynamic graph. The following outcome measures will be assessed at specific time points (Day 1, Day 7, Day 14, Day 21, and Day 28): 1. Reaction Time (R) (seconds) - The time from test initiation until the first detectable clot formation. 2. Kinetic Time (K) (seconds) - The time from initial clot formation to a defined clot strength threshold. 3. Maximum Amplitude (MA) (millimeters) - The peak strength of the formed clot. 4. Alpha Angle (degrees) - The slope of the clot formation curve, representing the rate of clot development. 5. Lysis at 30 Minutes (Ly30) (percentage of MA) - The percentage of clot degradation occurring 30 minutes after reaching maximum amplitude. Each parameter will be measured at the specified time points, and values will be aggregated into one TEG graph. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital Length of Stay | Duration of hospital length of stay, up to 28 days | The investigators will measure the number of days patients stay in the hospital for treatment. |
| Complications During Treatment | Duration of hospital length of stay, up to 28 days | The investigators will record any complications, such as infections, graft loss, flap loss, or thrombosis that occur during treatment. |
Countries
United States
Contacts
Primary ContactFrancesco M Egro, MD
Backup ContactHilary Y Liu, BS
Outcome results
None listed